Clinical trial
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
NCT02095548 is registered in ClinicalTrials.gov with Biosplice Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- September 30, 2015
- Enrollment
- 61 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe osteoarthritis